A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
PT-141, also known as bremelanotide, is FDA-approved (since June 2019, under the brand name Vyleesi) as the first on-demand medication for hypoactive sexual desire disorder in premenopausal women. It works by activating melanocortin receptors (MC3R and MC4R) in the brain’s reward and desire circuitry.
What genuinely sets PT-141 apart from more familiar options like Viagra or Cialis is the mechanism: PDE5 inhibitors work on blood flow and require desire to already be present — they don’t create arousal, they support the physical response once arousal exists. PT-141 works upstream of that, targeting the brain’s actual “wanting” system through dopamine reward pathways. That makes the two approaches complementary rather than interchangeable: PT-141 is the right tool when low desire itself is the issue, not when desire is present but the physical response isn’t following through.
“If sexual desire is the goal please start with testosterone. I hear people using this all the time without addressing testosterone first. Just because peptides are cool is no reason to abandon standard physiology and common sense.”
— Dr. Matt Chalmers, The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health
Nausea is the most common side effect, affecting roughly 40% of users, typically peaking 30–90 minutes after the dose and resolving within a few hours (pre-treatment with an anti-nausea medication substantially reduces this). Some people also experience a brief drop in blood pressure with a compensatory rise in heart rate, peaking 4–12 minutes after injection — which is why it’s not appropriate for people with uncontrolled high blood pressure or significant cardiovascular disease. A less common effect is temporary darkening of the skin on the face, gums, or breasts, which typically reverses once the medication is stopped.
PT-141 (bremelanotide) is FDA-approved under the brand name Vyleesi® for hypoactive sexual desire disorder in premenopausal women, at 1.75 mg by subcutaneous injection, up to once per 24 hours and no more than 8 doses per month. Use outside this approved indication (including off-label use in men) is considered off-label and is determined individually by your provider.
PT-141 (bremelanotide) is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women — the clinical trials supporting that approval documented its effect in that specific population. Use outside this approved indication is off-label and determined individually with your provider. Worth noting: our providers typically evaluate testosterone levels first, since low testosterone is a common and often overlooked contributor to low desire in both men and women.
Its documented mechanism is central (acting on melanocortin receptors in the brain) rather than acting on peripheral blood vessels, which is a distinct pathway from other approaches studied for sexual function.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
